1. Home /
  2. Biotechnology

Biotechnology

Grab Yourself a Cold Brew - Jim Cramer on Starbucks, Earnings and Mylan

Grab Yourself a Cold Brew - Jim Cramer on Starbucks, Earnings and Mylan

Jim Cramer tackles Starbucks, the Federal Reserve, earnings and Mylan ahead of a week filled with potentially market-moving headlines.

Exact Sciences in Talks to Buy Genomic Health - Report

Exact Sciences in Talks to Buy Genomic Health - Report

Cancer diagnostics company Exact Sciences is in advanced talks to acquire Genomic Health for about $2.8 billion to strengthen its cancer-testing offerings, according to Bloomberg.

Illumina Expected to Earn $1.34 a Share

Illumina Expected to Earn $1.34 a Share

Illumina revenue expected to rise 3.1% to $855.9 million.

Zimmer Biomet Jumps on Second-Quarter Earnings Beat

Zimmer Biomet Jumps on Second-Quarter Earnings Beat

Shares of orthopedic device maker Zimmer Biomet jump after the company reports second-quarter earnings and sales that beat analysts' forecasts.

AbbVie Rises on Strong Second-Quarter Results, Raised Guidance

AbbVie Rises on Strong Second-Quarter Results, Raised Guidance

Shares of drugmaker AbbVie gain after the company posts better-than-expected quarterly earnings and raises its guidance for the remainder of the year.

Building a Base, Moderna Finds Support at $13.50

Building a Base, Moderna Finds Support at $13.50

Without a lot of price history to work with, the charts show traders can approach the long side of MRNA risking a trade at $13.

Release Your 'Inner Spock' When Investing in Biotech Stocks

Release Your 'Inner Spock' When Investing in Biotech Stocks

Be zen and keep emotions out of investing decisions. It can pay off in higher portfolio returns.

Seattle Genetics Has a Rally in Its DNA

Seattle Genetics Has a Rally in Its DNA

Here's how to play this biotech stock.

Biogen Rises on Strong Second-Quarter Earnings, Guidance Boost

Biogen Rises on Strong Second-Quarter Earnings, Guidance Boost

The drugmaker reports second-quarter results that beat analysts' forecasts and raises its guidance for the remainder of the year on strong demand for its multiple sclerosis and other disease-fighting medications.

Acadia Falls Sharply in After-Hours Trading After Schizophrenia Drug Fails Study

Acadia Falls Sharply in After-Hours Trading After Schizophrenia Drug Fails Study

Stock drops as Pimavanserin study finds no statistically significant improvement in adult schizophrenia patients.